Skip to main content Help with accessibility Skip to main navigation

DAPAGLIFLOZIN, EMPAGLIFLOZIN, ERTUGLIFLOZIN, and CANAGLIFLOZIN as COMBINATION THERAPIES in type 2 diabetes: a multiple prescribing statement

CCG Approval Status:

Date Added: 23 - Sep - 2021
Body System:
Green

The Pan Mersey Area Prescribing Committee recommends the prescribing of CANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN and ERTUGLIFLOZIN as COMBINATION THERAPIES as options for treating type 2 diabetes in adults in accordance with NICE guidance.

Static